Latest News
Presentation is about methods for assessment of multiple molecular variables on a single piece of tissue to better understand breast cancer (or really any cancer) with respect to progression or response or resistance to specific therapies.
- August 22, 2022
The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its 2022 research grants, including six funded grants at Yale Cancer Center and Smilow Cancer Hospital awarded to Mehra Golshan, MD, MBA, Melinda Irwin, PhD, MPH, Ian Krop, MD, PhD, Lajos Pusztai, MD, DPhil, David Rimm, MD, PhD, and Eric Winer, MD to support their research.
- July 22, 2022
An objective assessment of automated electronic tumor infiltrating lymphocytes percentage (eTILs%) scores is a strong prognostic marker in patients with early-stage melanoma. The study also identifies distinct TIL subpopulations that carry the prognostic values.
- June 06, 2022Source: Fierce Biotech
With AstraZeneca and Daiichi Sankyo’s practice-changing clinical data for Enhertu in a new breast cancer category called HER2-low, experts have raised the necessity of revolutionizing the HER2 biomarker should be measured by diagnostic tests.
- May 20, 2022
Researchers at Yale Cancer Center have developed a new quantitative assay to measure the amount of HER2 protein in patients with breast cancer with increased accuracy. The improved data may provide new options for treatment for patients previously found ineligible for treatment based on traditional HER2 screening assays. The findings were published today in Laboratory Investigation.
- April 15, 2022Source: Healio
The use of current standard HER2 assays as diagnostic tests may result in misassignment of patients for treatment of breast cancer with trastuzumab deruxtecan, according to a study published in JAMA Oncology.
- March 30, 2022
This proposed research aims to find an alternative way to identify which persons with NSCLC will respond, and not respond, to this kind of treatment.
- March 18, 2022
Pathologists and research scientists from Department of Pathology at Yale School of Medicine will be involved in more than 40 presentations and sessions at the United States and Canadian Academy of Pathology (USCAP) 2022 Annual Meeting in Los Angeles March 19-24.
- February 18, 2022Source: YouTube
Aileen Fernandez, PhD, a Postdoctoral Fellow in the Department of Pathology at Yale School of Medicine, speaks with Shirley Malcolm, PhD, Senior Advisor to the Director of the American Association for the Advancement of Science and Director of its SEA Change initiative, which aims to advance institutional transformation in support of diversity, equity and inclusion, especially in colleges and universities.
- February 10, 2022Source: Medscape
Standard assays for ERBB2 like the one being used in trials of trastuzumab deruxtecan (T-DXd) for breast cancer could lead to misassignment of patients with few or no copies of the protein, according to researchers who include David Rimm, MD, PhD, of Yale Pathology.